Background: Melphalan, an alkylating agent, is an active chemotherapeutic agent in the treatment of multiple myeloma. High dose melphalan is used prior to autografting, but additional knowledge about the pharmacokinetics, combined with toxicity and efficacy data is needed to optimise the dose. Aims: To (1) investigate the pharmacokinetics of total and unbound plasma melphalan using a population approach […]
Christa Nath
- PAGANZ Inc Society Member
- The Children's Hospital at Westmead
Author Archive | Christa Nath
Population pharmacokinetics of melphalan in myeloma patients undergoing an autograft
January 9, 2008
Authors CE Nath (1), PJ Shaw(1,8), J Trotman (2), L Zeng (1), H Gurney (3), AJ McLachlan (2,8), I Kerridge (3), Y Kwan (2,6), P Presgrave (4), C Tiley (5), D Joshua (6), J Earl (1)
Affiliations (1) The Children
Presentation type Poster
Background: High dose melphalan is standard conditioning for autologous stem cell transplantation in the treatment of multiple myeloma. Appropriate dosing is critical as melphalan may be associated with profound toxicity, including cytopenia and gastrointestinal toxicity, which can lead to significant treatment-related mortality, while insufficient dose intensity can lead to disease relapse. The aim of this study was […]